The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

被引:201
作者
Giles, Francis J. [1 ]
Borthakur, Gautam [1 ]
Ravandi, Farhad [1 ]
Faderl, Stefan [1 ]
Verstovsek, Srdan [1 ]
Thomas, Deborah [1 ]
Wierda, William [1 ]
Ferrajoli, Alessandra [1 ]
Kornblau, Steven [1 ]
Pierce, Sherry [1 ]
Albitar, Maher [1 ]
Cortes, Jorge [1 ]
Kantarjian, Hagop [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
acute myeloid leukaemia; induction chemotherapy; comorbidity; prognosis;
D O I
10.1111/j.1365-2141.2006.06476.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The haematopoietic cell transplantation comorbidity index (HCTCI) predicts nonrelapse mortality and overall survival (OS) post-stem cell transplantation. HCTCI scores were assessed in 177 patients over 60 years of age receiving acute myeloid leukaemia (AML) induction therapy. HCTCI score was 0 in 22% of patients, 1-2 in 30%, and >= 3 in 48%. In patients with scores of 0, 1-2, or >= 3, early death rates were 3%, 11% and 29% (P < 0.001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy.
引用
收藏
页码:624 / 627
页数:4
相关论文
共 12 条
  • [1] Age and acute myeloid leukemia
    Appelbaum, FR
    Gundacker, H
    Head, DR
    Slovak, ML
    Willman, CL
    Godwin, JE
    Anderson, JE
    Petersdorf, SH
    [J]. BLOOD, 2006, 107 (09) : 3481 - 3485
  • [2] Treatment of older patients with acute myeloid leukemia - New agents
    Burnett, AK
    Mohite, U
    [J]. SEMINARS IN HEMATOLOGY, 2006, 43 (02) : 96 - 106
  • [3] VALIDATION OF A COMBINED COMORBIDITY INDEX
    CHARLSON, M
    SZATROWSKI, TP
    PETERSON, J
    GOLD, J
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1994, 47 (11) : 1245 - 1251
  • [4] Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:: Results from AMLSG trial AML HD98-B
    Froehling, Stefan
    Schlenk, Richard F.
    Kayser, Sabine
    Morhardt, Martina
    Benner, Axel
    Doehner, Konstanze
    Doehner, Hartmut
    [J]. BLOOD, 2006, 108 (10) : 3280 - 3288
  • [5] Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia
    Giles, Francis
    Rizzieri, David
    Karp, Judith
    Vey, Norbert
    Ravandi, Farhad
    Faderl, Stefan
    Khan, Khuda Dad
    Verhoef, Gregor
    Wijermans, Pierre
    Advani, Anjali
    Roboz, Gail
    Kantarjian, Hagop
    Bilgrami, Syed Fazl Ali
    Ferrant, Augustin
    Daenen, Simon M. G. J.
    Karsten, Verena
    Cahill, Ann
    Albitar, Maher
    Mufti, Ghulam
    O'Brien, Susan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) : 25 - 31
  • [6] Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy
    Gupta, V
    Chun, K
    Yi, QL
    Minden, M
    Schuh, A
    Wells, R
    Brandwein, J
    [J]. CANCER, 2005, 103 (10) : 2082 - 2090
  • [7] Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival
    Juliusson, G
    Billström, R
    Gruber, A
    Hellström-Linderg, E
    Höglund, M
    Karlsson, K
    Stockelberg, D
    Wahlin, A
    Åström, M
    Arnesson, C
    Brunell-Abrahamsson, U
    Carstensen, J
    Fredriksson, E
    Holmberg, E
    Nordenskjöld, K
    Wiklund, F
    [J]. LEUKEMIA, 2006, 20 (01) : 42 - 47
  • [8] Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome
    Kantarjian, H
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Jabbour, E
    Garcia-Manero, G
    Wierda, W
    Pierce, S
    Shan, JQ
    Estey, E
    [J]. CANCER, 2006, 106 (05) : 1090 - 1098
  • [9] Trends in the treatment of acute myeloid leukaemia in the elderly
    Lang, K
    Earle, CC
    Foster, T
    Dixon, D
    Van Gool, R
    Menzin, J
    [J]. DRUGS & AGING, 2005, 22 (11) : 943 - 955
  • [10] The outcomes and costs of acute myeloid leukemia among the elderly
    Menzin, J
    Lang, K
    Earle, CC
    Kerney, D
    Mallick, R
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (14) : 1597 - 1603